We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA’s Guideline on Carcinogenic Risk Evaluation Takes Effect in 2016
EMA’s Guideline on Carcinogenic Risk Evaluation Takes Effect in 2016
Drugmakers should develop assays, tests and other processes to identify and mitigate any impurities in their products that may cause cancer, according to a final guideline adopted by the European Medicines Agency.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor